0.6744

2.68% -0.0186

After Hours: .68 0.0056 +0.83%

Lexaria Bioscience Corp (LEXX)

Overview News Price History Financials Discussions Forecast Stock Split

Lexaria Bioscience Corp stock is traded at $0.6744, with a volume of 155.44K. It is down -2.68% in the last 24 hours and down -36.38% over the past month. Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.

Previous Close:

$0.693

Open:

$0.7

24h Volume:

155.44K

Relative Volume:

0.86

Market Cap:

$16.72M

Revenue:

$368.00K

Net Income/Loss:

$-9.54M

P/E Ratio:

-1.4085

EPS:

-0.4788

Net Cash Flow:

$-9.47M

1W Performance:

-2.10%

1M Performance:

-36.38%

6M Performance:

-37.56%

1Y Performance:

-37.56%

1-Day Range:

$0.6601

$0.7224

1-Week Range:

$0.5472

$0.7298

52-Week Range:

$0.46

$1.55

Lexaria Bioscience Corp Stock (LEXX) Company Profile

Name

Lexaria Bioscience Corp

Sector

Healthcare (1111)

Industry

Biotechnology (621)

Phone

250-765-6424

Address

100 - 740 MCCURDY ROAD, KELOWNA

Employee

Twitter

Next Earnings Date

2026-04-13

Latest SEC Filings

LEXX's Discussions on Twitter

Compare LEXX vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LEXX Lexaria Bioscience Corp	0.6744	17.18M	368.00K	-9.54M	-9.47M	-0.4788
VRTX Vertex Pharmaceuticals Inc	427.65	107.87B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	721.05	73.63B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	807.55	49.42B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	303.00	40.20B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	313.32	33.06B	5.36B	287.73M	924.18M	2.5229

Lexaria Bioscience Corp Stock (LEXX) Latest News

May 05, 2026

Lexaria Updates Progress on Human Study #7 - Investing News Network

May 05, 2026

Lexaria advances semaglutide study with ethics review submission - Investing.com

May 05, 2026

Lexaria advances semaglutide study with ethics review submission By Investing.com - Investing.com Australia

May 05, 2026

Lexaria targets mid-June start for 5-week oral semaglutide study - Stock Titan

May 05, 2026

Lexaria Bioscience stock soars after ending $5M stock sale agreement with JonesTrading - MSN

May 05, 2026

May 01, 2026

Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications - Investing News Network

May 01, 2026

Lexaria’s new video series zeroes in on a $75B GLP-1 market - Stock Titan

May 01, 2026

Apr 29, 2026

Lexaria Extends Material Transfer Agreement with PharmaCO Through 2026 for GLP-1 Drug Delivery Technology Evaluation - MEXC

Apr 29, 2026

Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended - Investing News Network

Apr 29, 2026

Lexaria Bioscience (LEXX) Extends Collaboration with PharmaCO Th - GuruFocus

Apr 29, 2026

Lexaria Bioscience (LEXX) Extends Collaboration with PharmaCO Through 2026 - GuruFocus

Apr 29, 2026

Lexaria extends pharma partnership to evaluate GLP-1 technology By Investing.com - Investing.com South Africa

Apr 29, 2026

Fit to Work: GLP-1 and Metabolic Health in the M&A Sector - Investing News Network

Apr 28, 2026

Apr 25, 2026

Lexaria Bioscience announces $2M registered direct offering; shares slip 19% - MSN

Apr 25, 2026

Apr 24, 2026

Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs - The Facts

Apr 24, 2026

Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales - The Facts

Apr 24, 2026

Apr 23, 2026

Lexaria Bioscience (LEXX) Advances Research with New Animal Stud - GuruFocus

Apr 23, 2026

Lexaria's 18-arm test will compare pills and capsules for two GLP-1 drugs - Stock Titan

Apr 23, 2026

Apr 21, 2026

Lexaria Bioscience: Drug Delivery Platform Innovator with Multiple Mainstream Applications - Investing News Network

Apr 21, 2026

Lexaria Bioscience (LEXX) Highlights Growth in GLP-1 Oral Market - GuruFocus

Apr 21, 2026

Weight-loss pill hit 600,000 scripts in 2 months as oral market builds - Stock Titan

Apr 21, 2026

Apr 20, 2026

Lexaria Bioscience (LEXX) Stock Profit Outlook (Trend Weakens) 2026-04-20Entry Points - Cổng thông tin điện tử tỉnh Tây Ninh

Apr 20, 2026

Apr 19, 2026

Can Lexaria Bioscience (NASDAQ:LEXX) Afford To Invest In Growth? - Sahm

Apr 19, 2026

Apr 18, 2026

Is Lexaria Bioscience (LEXX) stock an investment worth exploring (Eye on Rally) 2026-04-18Volume Leaders - Cổng thông tin điện tử tỉnh Tây Ninh

Apr 18, 2026